{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:44:59Z","timestamp":1764510299947},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4966,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1093\/annonc\/mdj994","type":"journal-article","created":{"date-parts":[[2006,5,15]],"date-time":"2006-05-15T17:27:50Z","timestamp":1147714070000},"page":"iv18-iv24","source":"Crossref","is-referenced-by-count":33,"special_numbering":"S4","title":["Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive\/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study"],"prefix":"10.1016","volume":"17","author":[{"given":"G.","family":"Corazzelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Capobianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Marcacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Della Cioppa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdj994_bb0010","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdj994_bb0015","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood.V77.7.1587.1587","article-title":"Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation","volume":"77","author":"Philip","year":"1991","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdj994_bb0020","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood.V91.4.1178","article-title":"Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma","volume":"91","author":"van Besien","year":"1998","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdj994_bb0025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3816\/CLM.2002.n.015","article-title":"Gemcitabine and its combinations in the treatment of malignant lymphoma","volume":"3","author":"Chau","year":"2002","journal-title":"Clin Lymphoma"},{"key":"10.1093\/annonc\/mdj994_bb0030","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3109\/10428199909058470","article-title":"The role of ifosfamide in the treatment of lymphomas","volume":"34","author":"Hagemeister","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdj994_bb0035","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.1999.17.12.3776","article-title":"Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin\u2019s lymphoma","volume":"17","author":"Moskowitz","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj994_bb0040","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdi003","article-title":"Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)","volume":"16","author":"Josting","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdj994_bb0045","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/cncr.21219","article-title":"Pro B et al. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma","volume":"104","author":"Oki","year":"2005","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdj994_bb0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002800050955","article-title":"Supraadditive effect of 2\u2032,2\u2032-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines","volume":"44","author":"Faivre","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdj994_bb0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/cbr.1997.12.177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1093\/annonc\/mdj994_bb0060","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2005.08.012","article-title":"Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin\u2019s lymphomas","volume":"23","author":"Khouri","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj994_bb0065","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj994_bb0070","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1200\/JCO.2005.01.891","article-title":"Response assessment of aggressive non-Hodgkin\u2019s lymphoma by integrated international workshop criteria and fluorine-18-fluorodeoxyglucose positron emission tomography","volume":"23","author":"Juweid","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj994_bb0075","first-page":"987","article-title":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","volume":"329","author":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdj994_bb0080","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/1097-0142(20010701)92:1<194::AID-CNCR1309>3.0.CO;2-3","article-title":"Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin","volume":"92","author":"Millikan","year":"2001","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdj994_bb0085","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdg496","article-title":"Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin\u2019s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Baetz","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdj994_bb0090","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/cncr.20587","article-title":"Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)","volume":"101","author":"Crump","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdj994_bb0095","first-page":"1205","article-title":"Clinical pharmacokinetics of oxaliplatin: a critical review","volume":"6","author":"Graham","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdj994_bb0100","first-page":"S26","article-title":"Preclinical studies of oxaliplatin in combination chemotherapy","volume":"88","author":"Raymond","year":"2001","journal-title":"Bull Cancer"},{"key":"10.1093\/annonc\/mdj994_bb0105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000077995","article-title":"Gemcitabine and cisplatin in refractory malignant lymphoma","volume":"66","author":"Aviles","year":"2004","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdj994_bb0110","doi-asserted-by":"crossref","first-page":"2483a","DOI":"10.1182\/blood.V104.11.2483.2483","article-title":"Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX): A promising regimen for refractory\/relapsed B-cell lymphoma","volume":"104","author":"El Gnaoui","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdj994_bb0115","doi-asserted-by":"crossref","first-page":"4597a","DOI":"10.1182\/blood.V104.11.4597.4597","article-title":"A stratified risk-adapted approach to lymphoma salvage in an outpatient setting","volume":"104","author":"Spencer","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdj994_bb0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/10428190400007540","article-title":"Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin\u2019s lymphoma?","volume":"46","author":"Wenger","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdj994_bb0125","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdj994_bb0130","first-page":"926","article-title":"Value of gemcitabine treatment in heavily pretreated Hodgkin\u2019s disease patients","volume":"85","author":"Zinzani","year":"2000","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdj994_bb0135","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419413677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419413677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/17\/suppl_4\/iv18\/436381\/mdj994.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T07:51:54Z","timestamp":1627372314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419413677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":26,"alternative-id":["S0923753419413677"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdj994","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}